Advertisement
Advertisement
REPL
Replimune Group, Inc.
12.36
USDSponsored
-0.24
-1.90%
Sep 25, 15:59 UTC -4
Closed
After-Market
12.40
+0.04
+0.33%
REPL Earnings Reports
Positive Surprise Ratio
REPL beat 17 of 33 last estimates.
52%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q2 27 (Revenue/ EPS)
--
/-$0.79
Implied change from Q1 27 (Revenue/ EPS)
--
/+9.72%
Implied change from Q2 26 (Revenue/ EPS)
--
/-12.22%
Replimune Group, Inc. earnings per share and revenue
On Aug 14, 2026, REPL reported earnings of -0.72 USD per share (EPS) for Q1 27, beating the estimate of -0.73 USD, resulting in a 1.69% surprise. Revenue reached --, compared to an expected 204.00 thousand, with a -100.00% difference. The market reacted with a -1.45% price change (close before vs. close after earnings).
Looking ahead to Q2 27, 4 analysts forecast an EPS of -0.79 USD, with revenue projected to reach -- USD, implying an increase of 9.72% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Replimune Group, Inc.'s earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Replimune Group, Inc. reported EPS of -$0.72, beating estimates by 1.69%, and revenue of $0.00, -100% below expectations.
How did the market react to Replimune Group, Inc.'s Q1 2027 earnings?
The stock price moved down -1.45%, changed from $15.19 before the earnings release to $14.97 the day after.
When is Replimune Group, Inc. expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Replimune Group, Inc.'s next earnings report?
Based on 4
analysts, Replimune Group, Inc. is expected to report EPS of -$0.79 and revenue of -- for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.